Previous 10 | Next 10 |
Palm Beach, FL – April 22, 2021 – Global Psychedelic and Psilocybin Drugs market is growing rapidly due to the increasing number of depression cases and rising special designation from the regulatory authorities to the company to expedite the development process of medicines. ...
Thanks to the COVID-19 pandemic, research shows that people are suffering more than ever from mental health conditions like depression, anxiety and PTSD, where conventional medicines provide little to no relief. For decades now, one of the most meaningful breakthroughs in mental health ther...
Over the last 20 years, “The number of psychopharmacological drugs research programs in larger drug firms has shrunk by 70% in the past decade,” reported The Guardian. “In general the larger companies have walked away from psychiatry. There are a few companies who have ...
It may only be a matter of time before mind-altering drugs make their way into Big Pharma treatments for mental health issues, such as depression, anxiety, obsessive compulsive disorder, trauma, and addiction. If that happens, the industry could be worth well over $100 billion, as noted by ...
Psychedelics could be a game-changer for millions dealing with depression, anxiety, addiction issues, PTSD, and even issues such as Parkinson’s disease. All of which is driving significant attention to companies like PharmaTher Holdings Ltd. (CSE: PHRM)(OTCQB: PHRRF), Mind Medi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s no secret that 2020 was a turning point for psychedelic stocks in the eyes of investors. The pandemic has precipitated a heightened focus on mental health and the inadequacies of our current standards of care. ...
People are quickly waking up to the potential benefits of psilocybin. In fact, former Texas Gov. Rick Perry just threw his support behind a bill that could create a study to look at psilocybin and its potential impact on veterans with PTSD. While Perry has said he’s “historica...
A new study published in the New England Journal of Medicine tested the use of psilocybin for depression treatment. Unfortunately for the psychedelic community, the results weren’t overwhelmingly different for psilocybin. The goal of the study was to compare the effec...
London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medic...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2021 – As an urgent public mental health crisis forces research institutions and governments to seriously examine unconventional mental health solutions, psychedelic assisted t...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...